Metformin suppresses sonic hedgehog expression in pancreatic cancer cells

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1765-1770

  Nakamura, Masafumi ^a   Ogo, Ayako ^a   Yamura, Masahiro ^a   Yamaguchi, Yoshiyuki ^a   Nakashima, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Hedgehog signaling pathway; Metformin; Pancreatic cancer; Sonic Hedgehog

Indexed keywords

MESSENGER RNA; METFORMIN; SONIC HEDGEHOG PROTEIN; ANTINEOPLASTIC AGENT;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEDGEHOG SIGNALING PATHWAY; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

HEDGEHOG SIGNALING PATHWAY; METFORMIN; PANCREATIC CANCER; SONIC HEDGEHOG;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; METFORMIN; PANCREATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84902290137     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nakamura M, Tanaka H, Nagayoshi Y, Nakashima H, Tsutsumi K, Ohtsuka T, Takahata S, Tanaka M and Okada H: Targeting the hedgehog signaling pathway with interacting peptides to Patched-1. J Gastroenterol 47 (4): 452-460, 2012.
2. Buchs AE and Silverman BG: Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism 60(10): 1379-1385, 2011.
3. Donadon V, Balbi M, Valent F and Avogaro A: Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 16(24): 3025-3032, 2010.
4. Gallagher EJ and LeRoith D: Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci 1243: 54-68, 2011.
5. Hsu C and Saif MW: Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA;
6. June 3-7, JOP 12 (4): 330-333, 2011.
7. Noto H, Goto A, Tsujimoto T, Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and metaanalysis. PLoS One 7(3): e33411, 2012.
8. Wysocki PJ and Wierusz-Wysocka B: Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 10(4): 509-519, 2010.
9. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M and Li D: Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10): 2905-2912, 2012.
10. Rozengurt E, Sinnett-Smith J and Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G proteincoupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16(9): 2505-2511, 2010.
11. Ozcimen EE, Uckuyu A, Ciftci FC and Zeyneloglu HB: The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome. Arch Gynecol Obstet 280(2): 263-269, 2009.
12. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C, Selimoglu H, Erturk E, Tuncel E and Imamoglu S: The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 81(1): 56-60, 2008.
13. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL and Hebrok M: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425(6960): 851-856, 2003.
14. Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM and Sarkar FH: Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 6(1): 77, 2013.
15. Rodova M, Fu J, Watkins DN, Srivastava RK and Shankar S: Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One 7(9): e46083, 2012.
16. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL and de Sauvage FJ: A paracrine requirement for hedgehog signalling in cancer. Nature 455(7211): 406-410, 2008.
17. Nakamura K, Sasajima J, Mizukami Y, Sugiyama Y, Yamazaki M, Fujii R, Kawamoto T, Koizumi K, Sato K, Fujiya M, Sasaki K, Tanno S, Okumura T, Shimizu N, Kawabe J, Karasaki H, Kono T, Ii M, Bardeesy N, Chung DC and Kohgo Y: Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived proangiogenic cells. PLoS One 5(1): e8824, 2010.
18. Goto Y, Sueoka E, Chiba H and Fujiki H: Significance of heterogeneous nuclear ribonucleoprotein B1 as a new early detection marker for oral squamous cell carcinoma. Jpn J Cancer Res 90(12): 1358-1363, 1999.
19. Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H and Katano M: Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in ERalphapositive gastric cancer. Br J Cancer 102(4): 738-747, 2010.
20. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9): 1620-1625, 2009.
21. Bodmer M, Meier C, Krahenbuhl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6): 1304-1308, 2010.
22. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20): 3297-3302, 2009.
23. He XX, Tu SM, Lee MH and Yeung SC: Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22(12): 2640-2645, 2011.
24. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275(1): 223-228, 2000.
25. Cip1. J Mol Signal 3: 18, 2008.
26. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69 (16): 6539-6545, 2009.
27. Xavier DO, Amaral LS, Gomes MA, Rocha MA, Campos PR, Cota BD, Tafuri LS, Paiva AM, Silva JH, Andrade SP and Belo AV: Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 64(3): 220-225, 2010.
28. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25): 3576-3586, 2008.
29. Alison MR, Lin WR, Lim SM and Nicholson LJ: Cancer stem cells: in the line of fire. Cancer Treat Rev 38(6): 589-598, 2008.
30. Deeb D, Gao X, Arbab AS, Barton K, Dulchavsky SA and Gautam SC: CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer. Cancers (Basel) 2(4): 1779-1793, 2010.
31. Aoki K, Yoshida T, Sugimura T and Terada M: Liposomemediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55 (17): 3810-3816, 1995.
32. Ma Y, Guo FC, Wang W, Shi HS, Li D and Wang YS: Kras gene mutation as a predictor of cancer cell responsiveness to metformin. Mol Med Rep 8(3): 763-768, 2013.
33. Galiana C, Fusco A, Martel N, Nishihira T, Hirohashi S and Yamasaki H: Possible role of activated ras genes in human esophageal carcinogenesis. Int J Cancer 54(6): 978-982, 1993.